Share Name Share Symbol Market Type Share ISIN Share Description
Gyg PLC LSE:GYG London Ordinary Share GB00BZ4FM652 ORD GBP0.002
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +1.50p +1.12% 135.00p 133.00p 137.00p 138.50p 134.00p 134.00p 15,026 14:49:12
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Industrial Transportation - - - - 62.96

Gyg PLC (GYG) Latest News

Gyg PLC News

Date Time Source Headline
15/9/201707:00UKREGGYG PLC Notice of Interim Results
19/7/201716:48UKREGGYG PLC Holding(s) in Company
13/7/201717:21UKREGGYG PLC Director/PDMR Shareholding
12/7/201714:50UKREGGYG PLC Holding(s) in Company
07/7/201709:46UKREGGYG PLC Holding(s) in Company
06/7/201711:38UKREGGYG PLC Holding(s) in Company
05/7/201712:45ALNCSuperyacht Services Firm GYG Begins Trading On AIM (ALLIPO)
05/7/201708:04UKREGGYG PLC Admission to AIM and First Day of Dealings
More Gyg PLC News
Gyg PLC Takeover Rumours

Gyg PLC (GYG) Share Charts

1 Year Gyg PLC Chart

1 Year Gyg PLC Chart

1 Month Gyg PLC Chart

1 Month Gyg PLC Chart

Intraday Gyg PLC Chart

Intraday Gyg PLC Chart

Gyg PLC (GYG) Discussions and Chat

Gyg PLC Forums and Chat

Date Time Title Posts
11/9/201708:28***GYG ***22
31/1/200821:13Gyrus Group 2006291
18/7/200710:51Gyrus group.6
24/3/200620:47gyrus read this88
16/3/200511:17gryus read this-

Add a New Thread

Gyg PLC (GYG) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Gyg PLC trades in real-time

Gyg PLC (GYG) Top Chat Posts

Gyg PLC Daily Update: Gyg PLC is listed in the Industrial Transportation sector of the London Stock Exchange with ticker GYG. The last closing price for Gyg PLC was 133.50p.
Gyg PLC has a 4 week average price of 117.50p and a 12 week average price of 104.50p.
The 1 year high share price is 629.50p while the 1 year low share price is currently 104.50p.
There are currently 46,640,000 shares in issue and the average daily traded volume is 18,583 shares. The market capitalisation of Gyg PLC is £62,964,000.
jonwig: Their NOMAD Zeus Capital has produced a very positive 44-page note implying H1 results are imminent, and won't have any upsets. Summary: At the current share price GYG trades on a 2017E P/E of 12.4x (falling to 10.0x in 2018E) and an EV/EBITDA of 8.6x (falling to 6.6x in 2018E), which we believe is compelling in the context of a 5.6% yield from 2018E. Our valuation is also supported by our DCF and intrinsic value analysis, which implies a valuation over €120m (£109m) if the strategy is executed successfully. A valuation of £109m would be a share price of 233p (!)
maddox: Rivaldo, Agreed, I would have expected anoter bidder to have thrown their hat into the ring by now. Also, the share price would have signalled an interest. This looks like a done deal. Regards, Maddox
rivaldo: The offer document's being published, so the Offer looks nailed on - getting a bit late for other approaches now. The share price should now approach the full 630p offered.
grigor: ... The offer, which values Gyrus at £935m, could be high enough to ward off interest from other bidders, although Paul Cuddon, an analyst at KBC Peel Hunt, said that Johnson & Johnson is unlikely to be comfortable with Olympus entering the market for general electrosurgical devices and may consider a counter-bid. Companies such as Stryker, ValleyLab and Pentax were also seen as possible suitors to rival the Japanese company's ambition. Mr Cudden said that some interested parties may have been surprised by the speed at which Olympus has done the deal, and that until the takeover completes, there is room for further share price upside. Any rival bid is likely could be complicated by the US regulators, due to the overlap in the major players' operations. The Nomura analyst Michael King said that the likes of Karl Storz, a leading supplier to the urology and gynaecology markets, may be interested in Gyrus, but the overlap may be too great for US regulators. For Olympus, the overlap between the two businesses is not as stark, with the Japanese company strongest in Japan and Europe, while Gyrus has a more dominant position in the US. ...
maddox: Wad, Not impressed by these results. I was expecting the dollar effect but the underlying growth is less than I expected. The share price fall also leads me to believe that they have not done anything to lower expectations ahead of these figures. With the Analysts giving a rosey picture, as Rivaldo has posted above, this disappointed reaction was a given. It doesn't pay to undermine the Analyst's confidence in the management team. Regards, Maddox
rivaldo: Stick with it wad collector imo - short-term is irrelevant if you're after decent gains of 50% or more as probably most of us on this thread have. For example, from yesterday: "Gyrus Posted on September 11th, 2007 in Market whispers. Morgan Stanley says the recent share price decline presents a buying opportunity. With a price target of 517p, broker says: 'Although Gyrus has experienced more than 10% share price decline in the last two months, we believe there is no fundamental reason for this.'"
rivaldo: Entj, I think you'll find FMR have actually top-sliced a few into the rise. Which makes the share price performance even more impressive. A snippet from the Mail today tells us a bit more about why JPM target 575p: "A JP Morgan recommendation helped Gyrus climb 27p to 515p. The broker says the company enjoys a core position in the US urology and gynaecology keyhole surgery market and is now entering the much larger surgery market."
rivaldo: Aha :o)) 575p here we come.... "Gyrus May 23rd, 2007 | Market whispers | No comments. JP Morgan likes the medical devices firm, which is actually a mini Smith & Nephew. It has initiated coverage of the stock with an overweight recommendation and 575p a share price target."
maddox: Wad, Hummmph, um not sure I actually gave advice, merely gave my own perspective. Anyway, I'm glad its worked out. Yep the Broker's recommendations are curious. I'm often perplexed by the 'buy'recommendation with a target that is one or two per cent ahead of the current share price. I saw one the other day that was a 'buy' and well below the current price? Your comment about valuations in the absence of a dividend is well made. However, I think its a question of whether they can make better use of the money than paying it out in dividends. I'd prefer to have capital growth than taxed dividends - at least in the short term. For example, if Gyrus are placing generators then the more capital they have available to do this the faster growth we will see. REgards, Maddox
maddox: Hi Guys, My investment style is long-term strategic. The current share price is by and large just market froth. This is a great company, with a sound strategy, a proven management team in a growing and expanding market. Everything else is largely irrelevant, including the dollar. You only need to look at the market trends, an aging affluent population; growing use of established keyhole surgery procedures (quicker, safer and more cost effective results); wider adoption of keyhole techniques to new procedures (e.g. general surgery); economic pressures on healthcare providers to move towards 'day case' provision. The share price will tend to move to either being above or below what can be taken to be fair value. It gives you the opportunity to either get in or get out at an acceptable price. The short term investment approaches essentially require you to try and second guess the market and avoid un-expected events (such as Dollar movements). The hair trigger investment style doesn't suit me, I've tried it and I cannot make it work. Regards, Maddox
Gyg PLC share price data is direct from the London Stock Exchange
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:42 V: D:20170921 15:43:38